Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells $309,621.50 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 28,802 shares of the stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total transaction of $309,621.50. Following the completion of the transaction, the insider directly owned 141,095 shares in the company, valued at $1,516,771.25. This trade represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mollie Leoni also recently made the following trade(s):

• On Monday, September 28th, Mollie Leoni sold 12,448 shares of Kura Oncology stock. The shares were sold at an average price of $10.50, for a total transaction of $130,704.00.

Kura Oncology Stock Performance

NASDAQ KURA traded up $0.20 during trading hours on Tuesday, hitting $10.81. The company had a trading volume of 1,890,260 shares, compared to its average volume of 1,673,937. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. Kura Oncology, Inc. has a 1-year low of $7.36 and a 1-year high of $13.90. The company has a market cap of $961.66 million, a PE ratio of -3.21 and a beta of 0.44. The business has a 50 day moving average of $11.22 and a 200-day moving average of $10.15.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. As a group, equities research analysts expect that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on KURA. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research report on Monday, August 24th. Raymond James Financial set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. Finally, Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a research note on Monday, August 24th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
• Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
• Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
• Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
• Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently modified their holdings of the stock. IFP Advisors Inc grew its position in Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Kura Oncology by 49.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after buying an additional 1,888 shares during the last quarter. Allworth Financial LP purchased a new position in Kura Oncology during the 2nd quarter worth $113,000. Pictet Asset Management Holding SA acquired a new stake in shares of Kura Oncology in the 1st quarter worth $96,000. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Kura Oncology in the 2nd quarter worth $132,000.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.